Frexalimab  (Synonyms: SAR441344; INX-021)

Frexalimab (SAR441344) is a second-generation monoclonal antibody targeting the CD40 ligand (CD40L) with a good safety profile. Frexalimab inhibits the binding between CD40 and CD40L to modulate immune response. Frexalimab is likely to help prevent the process of β-cell destruction. Frexalimab is proming for multiple sclerosis, lupus erythematosus, Sjögren’s syndrome and type I diabetes research^{[1][2][3][4][5]}.

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

Chimeric

2515463-86-0

Liquid

Colorless to light yellow

[Frexalimab]

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 kappa

• 
  Immobilized Human CD40 Ligand/TNFSF5 Protein (His Tag) can bind Frexalimab. The EC₅₀ for this effect is 2.43 ng/mL.
• 
  Loaded CD40L/CD154/TRAP Protein, Human (HEK293, Tag free, HY-P70609) on AHC2 biosensor, can bind Frexalimab with an affinity constant of 4.117E-10 M as determined in BLI assay.

• [1]. Bruce A C Cree, et al. New drugs for multiple sclerosis: new treatment algorithms. Curr Opin Neurol. 2022 Jun 1;35(3):262-270.  [Content Brief]

  [2]. Vermersch P, et al. Inhibition of CD40L with Frexalimab in Multiple Sclerosis. N Engl J Med. 2024 Feb 15;390(7):589-600.  [Content Brief]

  [3]. Carvalho T. Anti-CD40L antibody frexalimab slows new brain lesions in multiple sclerosis. Nat Med. 2023 Aug;29(8):1882-1883.  [Content Brief]

  [4]. Weiskorn J, et al. Moving from Insulin Substitution to the Treatment of the Underlying Autoimmune Disease in Type 1 Diabetes. Horm Res Paediatr. 2024 Apr 30:1-8.  [Content Brief]

  [5]. Maddaloni E, et al. Immune checkpoint modulators in early clinical development for the treatment of type 1 diabetes. Expert Opin Investig Drugs. 2024 Apr;33(4):303-318.  [Content Brief]